Zenas BioPharma, Inc.
ZBIO
$19.16
-$1.24-6.08%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -377.74M | -189.90M | -177.01M | -162.76M | -156.99M |
| Total Depreciation and Amortization | 56.00K | 79.00K | 104.00K | 127.00K | 137.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 204.40M | 29.85M | 18.79M | 15.30M | 11.75M |
| Change in Net Operating Assets | 951.00K | 1.50M | 9.71M | 9.71M | 25.43M |
| Cash from Operations | -172.33M | -158.47M | -148.41M | -137.62M | -119.67M |
| Capital Expenditure | -18.00K | -92.00K | -92.00K | -127.00K | -131.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -251.87M | -162.17M | -228.97M | -116.68M | -30.42M |
| Cash from Investing | -251.89M | -162.26M | -229.06M | -116.80M | -30.55M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 152.95M | 9.09M | 242.57M | 240.97M | 240.91M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | 0.00 | 0.00 | 178.38M | 178.38M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 62.34M | 67.20M | -4.91M | -5.68M | -6.33M |
| Cash from Financing | 215.28M | 76.29M | 237.65M | 413.67M | 412.96M |
| Foreign Exchange rate Adjustments | -252.00K | -122.00K | -199.00K | 69.00K | 157.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -209.19M | -244.56M | -140.01M | 159.31M | 262.89M |